Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

PCDH11X mutation as a potential biomarker for immune checkpoint therapies in lung adenocarcinoma.

Journal of molecular medicine (Berlin, Germany) - 1 Jul 2024

Liu Manjiao, Yang Meijia, Zhang Bei, Xia Sijian, Zhao Jie, Yan Linlin, Ren Yong, Guo Hao, Zhao Jie

Abstract excerpt

Immune checkpoint inhibitors (ICIs) have achieved impressive success in lung adenocarcinoma (LUAD). However, the response to ICIs varies among patients, and predictive biomarkers are urgently needed. PCDH11X is frequently mutated in LUAD, while its role in ICI treatment is unclear. In this study, we curated genomic and clinical data of 151 LUAD patients receiving ICIs from three independent cohorts. Relations...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma of Lung
Share to Biomarkers, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cadherins

Share to Cohort Studies

Share to Immune Checkpoint Inhibitors

Share to Lung Neoplasms

Share to Prognosis

Share to Protocadherins

Source

Identifiers

PMID: 38739269
DOI: 10.1007/s00109-024-02450-8

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PCDH11X mutation as a potential biomarker for immune checkpoint therapies in lung adenocarcinoma.PMID 38739269Read ↗

Predictive value of ZFHX4 mutation for the efficacy of immune checkpoint inhibitors in non-small cell lung cancer and melanoma.Semantic proximity Read ↗

COL22A1 and DNAH8 mutations are associated with tumor mutation burden and prognosis of lung adenocarcinoma patientsSemantic proximity Read ↗

Less immune cell infiltration and worse prognosis after immunotherapy for patients with lung adenocarcinoma who harbored STK11 mutation.Semantic proximity Read ↗

A programmed cell death-related model based on machine learning for predicting prognosis and immunotherapy responses in patients with lung adenocarcinomaSemantic proximity Read ↗

<i>STK11</i> and <i>KEAP1</i> Mutations as Prognostic Biomarkers in an Observational Real-World Lung Adenocarcinoma CohortSemantic proximity Read ↗

In-Depth Genomic Characterization of Programmed Cell Death Ligand 1 (PD-L1) Expression in Chinese Lung Adenocarcinoma PatientsSemantic proximity Read ↗

DYNC2H1 mutation as a potential predictive biomarker for immune checkpoint inhibitor efficacy in NSCLC and melanoma.Semantic proximity Read ↗

The association of genomic alterations with PD-L1 expression in Chinese patients with EGFR/ALK wild-type lung adenocarcinoma and potential predictive value of Hippo pathway mutations to immunotherapy.Semantic proximity Read ↗

Association of MSH2 Expression With Tumor Mutational Burden and the Immune Microenvironment in Lung AdenocarcinomaSemantic proximity Read ↗

HYDIN mutation status as a potential predictor of immune checkpoint inhibitor efficacy in melanoma.Semantic proximity Read ↗

Prevalence of PRKDC mutations and association with response to immune checkpoint inhibitors in solid tumors.Semantic proximity Read ↗

Lung adenocarcinoma patients with KEAP1 mutation harboring low immune cell infiltration and low activity of immune environment.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.